Treatment with Human Mesenchymal Stem Cells (Remestemcel-L) Is Effective in Pediatric Patients with Refractory Acute Graft Versus Host Disease

Joanne Kurtzberg(Duke University), Donna Skerrett(Mesoblast (United States)), Pierre Teira(Université de Montréal), Eneida R. Nemecek(Oregon Health & Science University), Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Jack Hayes(Mesoblast (United States)), Sonali Chaudhury(Northwestern University), Vinod K. Prasad(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Biljana Horn(UF Health Shands Hospital), Elizabeth Burke(Mesoblast (United States))
Transplantation and Cellular Therapy
January 22, 2015
10.1016/j.bbmt.2014.11.539
Cited by 1

Related Papers

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
|Blood|2010|477
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369